Overview of new drugs and prices of ensidipine for the treatment of AML

Enasidenib (Enasidenib) is a targeted therapy drug specifically for relapsed or refractory acute myeloid leukemia (AML), especially for patients with isocitrate dehydrogenase 2 (IDH2) gene mutations. IDH2 gene mutations play an important role in the pathogenesis of AML, which can lead to the malignant proliferation of leukemia cells. Ensidipine can restore the normal function of cells by precisely inhibiting the enzyme activity of this mutation.

Different from traditional chemotherapy drugs, ensidipine uses a new treatment strategy. It does not directly kill leukemia cells, but reduces the production of abnormal metabolite 2-hydroxygluconic acid (2-HG) by regulating intracellular metabolic pathways. This unique mechanism allows ensidipine to reduce the interference of 2-HG on the normal hematopoietic process, thereby restoring the normal differentiation of cells, effectively inhibiting the growth of leukemia cells and inducing them to undergo apoptosis.

In clinical trials, ensidipine has demonstrated impressive therapeutic effects. For AML patients carryingIDH2 gene mutations, the drug not only brings a higher complete remission rate, but also significantly extends the duration of the patient's remission. These encouraging data strongly confirm the superior efficacy of ensidipine in treating this specific patient population.

For many patients, however, the price of a drug is also a focus. Since encidipine is not yet available in the country, it currently cannot enjoy preferential policies for medical insurance reimbursement. For patients who are in urgent need of this innovative drug, they can obtain it through overseas purchase or consultation with professional overseas medical consulting companies. It is understood that generic versions of ensidipine are currently available in overseas markets, such as products produced by Zisika Pharmaceuticals in Bangladesh and Lucius Pharmaceuticals in Laos. The price is approximately more than 2,000 yuan per box (containing 30 tablets).

In summary, ensidipine, as a new drug for relapsed or refractory AML, provides a new and highly effective treatment option for patients carrying IDH2 gene mutations. Its unique therapeutic mechanism and significant clinical effects have undoubtedly injected new vitality into the field of leukemia treatment. At the same time, as more patients pay attention to and demand this drug, we also expect that ensidipine can enter the domestic market at a more reasonable price in the future, benefiting more patients.